A NIR-light activated nanoplatform for sensitizing triple negative breast cancer against therapeutic resistance to enhance the treatment effect
Current therapeutic strategies against triple negative breast cancer (TNBC) are limited by unconquered therapeutic resistance that shields TNBC cells from treatments such as chemotherapy and radiotherapy. Therefore, the construction of therapeutics capable of sensitizing TNBC cells towards conventional therapeutic strategies remains a formidable challenge in phymatology. Here, a NIR-light activated combination therapeutic nanoplatform is reported to cure TNBC by gene-silencing based sensitization of cancer cells toward treatment using mesoporous silica-coated gold nanorods (Au@MSNs) modified with DNAzyme, which can catalytically cleave survivin mRNA. The survivin DNAzyme is chemically modified on the surface of Au@MSNs using a thermally sensitive small molecule. Upon NIR light irradiation, the absorbed NIR light by gold nanorods is converted into heat to trigger bond breaking, releasing DNAzyme to silence survivin mRNA and sensitize TNBC. In vitro and in vivo results reveal the excellent therapeutic effects of this multifunctional nanocomposite against TNBC.